FR04C0024I2 - - Google Patents

Info

Publication number
FR04C0024I2
FR04C0024I2 FR04C0024C FR04C0024C FR04C0024I2 FR 04C0024 I2 FR04C0024 I2 FR 04C0024I2 FR 04C0024 C FR04C0024 C FR 04C0024C FR 04C0024 C FR04C0024 C FR 04C0024C FR 04C0024 I2 FR04C0024 I2 FR 04C0024I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR04C0024C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of FR04C0024I1 publication Critical patent/FR04C0024I1/fr
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Application granted granted Critical
Publication of FR04C0024I2 publication Critical patent/FR04C0024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR04C0024C 1992-11-30 2004-10-22 Active FR04C0024I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (2)

Publication Number Publication Date
FR04C0024I1 FR04C0024I1 (de) 2004-03-12
FR04C0024I2 true FR04C0024I2 (de) 2010-12-31

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
FR04C0024C Active FR04C0024I2 (de) 1992-11-30 2004-10-22

Country Status (15)

Country Link
US (1) US5635213A (de)
EP (1) EP0670713B3 (de)
JP (1) JP3661703B2 (de)
AT (1) ATE184191T3 (de)
AU (1) AU688290B2 (de)
CA (1) CA2150464C (de)
DE (2) DE122005000021I1 (de)
DK (1) DK0670713T3 (de)
ES (1) ES2137350T7 (de)
FR (1) FR04C0024I2 (de)
GR (1) GR3031988T3 (de)
NL (1) NL300169I1 (de)
NZ (1) NZ258276A (de)
SE (1) SE9203594D0 (de)
WO (1) WO1994012153A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (de) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
EP2063865A1 (de) * 2006-05-31 2009-06-03 Solvay Pharmaceuticals GmbH Langfristige intestinale 24-stunden-verabreichung von levodopa/carbidopa
EP2359808B1 (de) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotisches Verabreichungssystem mit Kolbenanordnung
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8779094B2 (en) 2008-11-16 2014-07-15 Board Of Regents, The University Of Texas System Low viscosity highly concentrated suspensions
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2653179B1 (de) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System zur Berechnung und zur Verabreichung eines Medikaments an einem Patienten mit Morbus Parkinson
US10071069B2 (en) 2014-09-04 2018-09-11 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3487479A1 (de) * 2016-07-20 2019-05-29 AbbVie Inc. Levodopa- und carbidopadarmgel und verfahren zur verwendung
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3758754A1 (de) 2018-03-02 2021-01-06 Chiesi Farmaceutici S.p.A. Pharmazeutische formulierung zur intraduodenalen verabreichung mit melevodopa und carbidopa
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
ES2137350T3 (es) 1999-12-16
ATE184191T3 (de) 1999-09-15
GR3031988T3 (en) 2000-03-31
NL300169I1 (nl) 2005-03-01
SE9203594D0 (sv) 1992-11-30
EP0670713B3 (de) 2016-10-05
EP0670713A1 (de) 1995-09-13
EP0670713B1 (de) 1999-09-08
DE69326350T3 (de) 2018-01-11
DE122005000021I1 (de) 2006-02-23
CA2150464C (en) 2002-02-05
DK0670713T3 (da) 2000-03-20
JP3661703B2 (ja) 2005-06-22
AU688290B2 (en) 1998-03-12
FR04C0024I1 (de) 2004-03-12
JPH08504764A (ja) 1996-05-21
DE69326350T2 (de) 2000-01-27
AU5583694A (en) 1994-06-22
NZ258276A (en) 1996-09-25
US5635213A (en) 1997-06-03
CA2150464A1 (en) 1994-06-09
ES2137350T7 (es) 2017-11-13
DE69326350D1 (de) 1999-10-14
WO1994012153A1 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
FR04C0024I2 (de)
TW227608B (de)
BR9304651A (de)
TW250604B (de)
DE9200249U1 (de)
DE9200057U1 (de)
TW224495B (de)
TW242582B (de)
DE9200236U1 (de)
DE9200240U1 (de)
DE9200047U1 (de)
DE9200245U1 (de)
DE9200172U1 (de)
DE9204125U1 (de)
DE9200056U1 (de)
DE9200256U1 (de)
DE9200280U1 (de)
DE9200290U1 (de)
AU631518B2 (de)
DE9200274U1 (de)
IN178311B (de)
DE9200224U1 (de)
DE9211267U1 (de)
DE9200174U1 (de)
DE9200042U1 (de)